Two years after Gilead’s drug first emerged as an option against COVID-19, Veklury is back in the spotlight.
Originally developed as a medicine for hepatitis C and Ebola, Veklury became the first drug proven effective in treating COVID-19. It is still the only coronavirus medicine with a standard approval from the FDA. (Others are authorized for emergency use.) Sales of Veklury have earned Gilead more than $7 billion since the drug was first granted an emergency clearance in May 2020.
